Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 374

1.

Binding of monovalent and bivalent ligands by transthyretin causes different short and long distance conformational changes.

Corazza A, Verona G, Waudby CA, Mangione PP, Bingham RP, Uings I, Canetti D, Nocerino P, Taylor GW, Pepys MB, Christodoulou JC, Bellotti V.

J Med Chem. 2019 Aug 8. doi: 10.1021/acs.jmedchem.9b01037. [Epub ahead of print]

PMID:
31393717
2.

The Pentraxins 1975-2018: Serendipity, Diagnostics and Drugs.

Pepys MB.

Front Immunol. 2018 Oct 16;9:2382. doi: 10.3389/fimmu.2018.02382. eCollection 2018.

3.

Plasminogen activation triggers transthyretin amyloidogenesis in vitro.

Mangione PP, Verona G, Corazza A, Marcoux J, Canetti D, Giorgetti S, Raimondi S, Stoppini M, Esposito M, Relini A, Canale C, Valli M, Marchese L, Faravelli G, Obici L, Hawkins PN, Taylor GW, Gillmore JD, Pepys MB, Bellotti V.

J Biol Chem. 2018 Sep 14;293(37):14192-14199. doi: 10.1074/jbc.RA118.003990. Epub 2018 Jul 17.

4.

Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1.

Borthwick NJ, Lane T, Moyo N, Crook A, Shim JM, Baines I, Wee EG, Hawkins PN, Gillmore JD, Hanke T, Pepys MB.

PLoS One. 2018 May 17;13(5):e0197299. doi: 10.1371/journal.pone.0197299. eCollection 2018.

5.

Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.

Richards DB, Cookson LM, Barton SV, Liefaard L, Lane T, Hutt DF, Ritter JM, Fontana M, Moon JC, Gillmore JD, Wechalekar A, Hawkins PN, Pepys MB.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaan3128. doi: 10.1126/scitranslmed.aan3128.

PMID:
29298867
6.

Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies.

Mangione PP, Mazza G, Gilbertson JA, Rendell NB, Canetti D, Giorgetti S, Frenguelli L, Curti M, Rezk T, Raimondi S, Pepys MB, Hawkins PN, Gillmore JD, Taylor GW, Pinzani M, Bellotti V.

J Proteomics. 2017 Aug 8;165:113-118. doi: 10.1016/j.jprot.2017.06.016. Epub 2017 Jun 21.

7.

Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel.

Verona G, Mangione PP, Raimondi S, Giorgetti S, Faravelli G, Porcari R, Corazza A, Gillmore JD, Hawkins PN, Pepys MB, Taylor GW, Bellotti V.

Sci Rep. 2017 Mar 15;7(1):182. doi: 10.1038/s41598-017-00338-x.

8.

Immunotherapeutic clearance of systemic amyloid deposits by antibodies to serum amyloid P component.

Pepys MB.

Amyloid. 2017 Mar;24(sup1):5-6. doi: 10.1080/13506129.2016.1269735. Epub 2016 Dec 26. No abstract available.

PMID:
28019722
9.

Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo.

Al-Shawi R, Tennent GA, Millar DJ, Richard-Londt A, Brandner S, Werring DJ, Simons JP, Pepys MB.

Open Biol. 2016 Feb;6(2):150202. doi: 10.1098/rsob.150202.

10.

Multinucleated Giant Cells Are Specialized for Complement-Mediated Phagocytosis and Large Target Destruction.

Milde R, Ritter J, Tennent GA, Loesch A, Martinez FO, Gordon S, Pepys MB, Verschoor A, Helming L.

Cell Rep. 2015 Dec 1;13(9):1937-48. doi: 10.1016/j.celrep.2015.10.065. Epub 2015 Nov 25.

11.

Bifunctional crosslinking ligands for transthyretin.

Mangione PP, Deroo S, Ellmerich S, Bellotti V, Kolstoe S, Wood SP, Robinson CV, Smith MD, Tennent GA, Broadbridge RJ, Council CE, Thurston JR, Steadman VA, Vong AK, Swain CJ, Pepys MB, Taylor GW.

Open Biol. 2015 Sep;5(9):150105. doi: 10.1098/rsob.150105.

12.

A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis.

Marcoux J, Mangione PP, Porcari R, Degiacomi MT, Verona G, Taylor GW, Giorgetti S, Raimondi S, Sanglier-Cianférani S, Benesch JL, Cecconi C, Naqvi MM, Gillmore JD, Hawkins PN, Stoppini M, Robinson CV, Pepys MB, Bellotti V.

EMBO Mol Med. 2015 Oct;7(10):1337-49. doi: 10.15252/emmm.201505357.

13.

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.

Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, Fontana M, Moon JC, Pinzani M, Gillmore JD, Hawkins PN, Pepys MB.

N Engl J Med. 2015 Sep 17;373(12):1106-14. doi: 10.1056/NEJMoa1504942. Epub 2015 Jul 15.

14.

Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC).

Kolstoe SE, Jenvey MC, Purvis A, Light ME, Thompson D, Hughes P, Pepys MB, Wood SP.

Acta Crystallogr D Biol Crystallogr. 2014 Aug;70(Pt 8):2232-40. doi: 10.1107/S1399004714013455. Epub 2014 Jul 25.

15.

Targeted treatment for amyloidosis.

Pepys-Vered ME, Pepys MB.

Isr Med Assoc J. 2014 May;16(5):277-80. No abstract available.

16.

C-reactive protein is essential for innate resistance to pneumococcal infection.

Simons JP, Loeffler JM, Al-Shawi R, Ellmerich S, Hutchinson WL, Tennent GA, Petrie A, Raynes JG, de Souza JB, Lawrence RA, Read KD, Pepys MB.

Immunology. 2014 Jul;142(3):414-20. doi: 10.1111/imm.12266.

17.

Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis.

Mangione PP, Porcari R, Gillmore JD, Pucci P, Monti M, Porcari M, Giorgetti S, Marchese L, Raimondi S, Serpell LC, Chen W, Relini A, Marcoux J, Clatworthy IR, Taylor GW, Tennent GA, Robinson CV, Hawkins PN, Stoppini M, Wood SP, Pepys MB, Bellotti V.

Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1539-44. doi: 10.1073/pnas.1317488111. Epub 2014 Jan 13.

18.

Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers.

Lane T, Wassef N, Poole S, Mistry Y, Lachmann HJ, Gillmore JD, Hawkins PN, Pepys MB.

Circ Res. 2014 Feb 14;114(4):672-6. doi: 10.1161/CIRCRESAHA.114.302770. Epub 2013 Dec 12.

PMID:
24337102
19.

Structure, folding dynamics, and amyloidogenesis of D76N β2-microglobulin: roles of shear flow, hydrophobic surfaces, and α-crystallin.

Mangione PP, Esposito G, Relini A, Raimondi S, Porcari R, Giorgetti S, Corazza A, Fogolari F, Penco A, Goto Y, Lee YH, Yagi H, Cecconi C, Naqvi MM, Gillmore JD, Hawkins PN, Chiti F, Rolandi R, Taylor GW, Pepys MB, Stoppini M, Bellotti V.

J Biol Chem. 2013 Oct 25;288(43):30917-30. doi: 10.1074/jbc.M113.498857. Epub 2013 Sep 6.

20.

Pathogenetic mechanisms of amyloid A amyloidosis.

Simons JP, Al-Shawi R, Ellmerich S, Speck I, Aslam S, Hutchinson WL, Mangione PP, Disterer P, Gilbertson JA, Hunt T, Millar DJ, Minogue S, Bodin K, Pepys MB, Hawkins PN.

Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16115-20. doi: 10.1073/pnas.1306621110. Epub 2013 Aug 19.

21.

Monitoring systemic amyloidosis using MRI measurements of the extracellular volume fraction.

Campbell-Washburn AE, Price AN, Ellmerich S, Simons JP, Al-Shawi R, Kalber TL, Ghatrora R, Hawkins PN, Moon JC, Ordidge RJ, Pepys MB, Lythgoe MF.

Amyloid. 2013 Jun;20(2):93-8. doi: 10.3109/13506129.2013.787984. Epub 2013 Apr 26.

PMID:
23621497
22.

Distribution and determinants of circulating complement factor H concentration determined by a high-throughput immunonephelometric assay.

Sofat R, Mangione PP, Gallimore JR, Hakobyan S, Hughes TR, Shah T, Goodship T, D'Aiuto F, Langenberg C, Wareham N, Morgan BP, Pepys MB, Hingorani AD.

J Immunol Methods. 2013 Apr 30;390(1-2):63-73. doi: 10.1016/j.jim.2013.01.009. Epub 2013 Jan 30.

PMID:
23376722
23.

C-reactive protein, fibrinogen, and cardiovascular disease prediction.

Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E, Benjamin EJ, Björkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D'Agostino RB Sr, Dankner R, Davey-Smith G, Deeg D, Dekker JM, Engström G, Folsom AR, Fowkes FG, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, Jørgensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CD, Strandberg TE, Tipping RW, Tosetto A, Wassertheil-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GD, Wareham NJ, Khaw KT, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J.

N Engl J Med. 2012 Oct 4;367(14):1310-20. doi: 10.1056/NEJMoa1107477.

24.

Invasive candidiasis: new insights presaging new therapeutic approaches?

Pepys MB.

J Infect Dis. 2012 Nov;206(9):1339-41. doi: 10.1093/infdis/jis521. Epub 2012 Aug 22. No abstract available.

PMID:
22927458
25.

Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use.

Pepys MB, Gallimore JR, Lloyd J, Li Z, Graham D, Taylor GW, Ellmerich S, Mangione PP, Tennent GA, Hutchinson WL, Millar DJ, Bennett G, More J, Evans D, Mistry Y, Poole S, Hawkins PN.

J Immunol Methods. 2012 Oct 31;384(1-2):92-102. doi: 10.1016/j.jim.2012.07.013. Epub 2012 Jul 31.

26.

Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin.

Valleix S, Gillmore JD, Bridoux F, Mangione PP, Dogan A, Nedelec B, Boimard M, Touchard G, Goujon JM, Lacombe C, Lozeron P, Adams D, Lacroix C, Maisonobe T, Planté-Bordeneuve V, Vrana JA, Theis JD, Giorgetti S, Porcari R, Ricagno S, Bolognesi M, Stoppini M, Delpech M, Pepys MB, Hawkins PN, Bellotti V.

N Engl J Med. 2012 Jun 14;366(24):2276-83. doi: 10.1056/NEJMoa1201356.

27.

Immunoradiometric assay for human serum amyloid P component.

Millar DJ, Hutchinson WL, Pepys MB.

J Immunol Methods. 2011 Aug 31;371(1-2):18-24. doi: 10.1016/j.jim.2011.06.010. Epub 2011 Jun 25.

PMID:
21708157
28.

Structural basis of ligand specificity in the human pentraxins, C-reactive protein and serum amyloid P component.

Mikolajek H, Kolstoe SE, Pye VE, Mangione P, Pepys MB, Wood SP.

J Mol Recognit. 2011 Mar-Apr;24(2):371-7. doi: 10.1002/jmr.1090.

PMID:
21360619
29.

Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data.

C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC), Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, Engert JC, Clarke R, Davey-Smith G, Nordestgaard BG, Saleheen D, Samani NJ, Sandhu M, Anand S, Pepys MB, Smeeth L, Whittaker J, Casas JP, Thompson SG, Hingorani AD, Danesh J.

BMJ. 2011 Feb 15;342:d548. doi: 10.1136/bmj.d548.

30.

Trapping of palindromic ligands within native transthyretin prevents amyloid formation.

Kolstoe SE, Mangione PP, Bellotti V, Taylor GW, Tennent GA, Deroo S, Morrison AJ, Cobb AJ, Coyne A, McCammon MG, Warner TD, Mitchell J, Gill R, Smith MD, Ley SV, Robinson CV, Wood SP, Pepys MB.

Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20483-8. doi: 10.1073/pnas.1008255107. Epub 2010 Nov 8.

31.

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB.

Nature. 2010 Nov 4;468(7320):93-7. doi: 10.1038/nature09494. Epub 2010 Oct 20.

32.

Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.

Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, Offer M, Millar DJ, Petrie A, Hawkins PN, Pepys MB.

Br J Haematol. 2010 Mar;148(5):760-7. doi: 10.1111/j.1365-2141.2009.08036.x. Epub 2010 Jan 8.

PMID:
20064157
33.

Lack of effect of a single injection of human C-reactive protein on murine lupus or nephrotoxic nephritis.

Carlucci F, Cook HT, Garg A, Pepys MB, Botto M.

Arthritis Rheum. 2010 Jan;62(1):245-9. doi: 10.1002/art.27232.

34.

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.

Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J.

Lancet. 2010 Jan 9;375(9709):132-40. doi: 10.1016/S0140-6736(09)61717-7. Epub 2009 Dec 22.

35.

C-reactive protein and coronary disease: is there a causal link?

Danesh J, Pepys MB.

Circulation. 2009 Nov 24;120(21):2036-9. doi: 10.1161/CIRCULATIONAHA.109.907212. Epub 2009 Nov 9. No abstract available.

PMID:
19901186
36.

Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.

Kolstoe SE, Ridha BH, Bellotti V, Wang N, Robinson CV, Crutch SJ, Keir G, Kukkastenvehmas R, Gallimore JR, Hutchinson WL, Hawkins PN, Wood SP, Rossor MN, Pepys MB.

Proc Natl Acad Sci U S A. 2009 May 5;106(18):7619-23. doi: 10.1073/pnas.0902640106. Epub 2009 Apr 16.

37.

A molecular correlate of clinicopathology in transthyretin amyloidosis.

Pepys MB.

J Pathol. 2009 Jan;217(1):1-3. doi: 10.1002/path.2467. Review.

PMID:
19061244
38.

C-reactive protein and coronary heart disease: a critical review.

Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB.

J Intern Med. 2008 Oct;264(4):295-314. doi: 10.1111/j.1365-2796.2008.02015.x. Review.

39.

Complement factor H binds to denatured rather than to native pentameric C-reactive protein.

Hakobyan S, Harris CL, van den Berg CW, Fernandez-Alonso MC, de Jorge EG, de Cordoba SR, Rivas G, Mangione P, Pepys MB, Morgan BP.

J Biol Chem. 2008 Nov 7;283(45):30451-60. doi: 10.1074/jbc.M803648200. Epub 2008 Sep 11.

40.

Jack Pepys (May 15, 1914-September 9, 1996): a personal recollection.

Pepys MB.

J Allergy Clin Immunol. 2009 Mar;123(3):718-20. doi: 10.1016/j.jaci.2008.05.039. Epub 2008 Jun 27. No abstract available.

PMID:
18585767
41.

C-reactive protein is neither a marker nor a mediator of atherosclerosis.

Pepys MB.

Nat Clin Pract Nephrol. 2008 May;4(5):234-5. doi: 10.1038/ncpneph0778. Epub 2008 Mar 4. Review. No abstract available.

PMID:
18317503
42.

Science and serendipity.

Pepys MB.

Clin Med (Lond). 2007 Dec;7(6):562-78. Review.

43.

Disease-associated prion protein is not detectable in human systemic amyloid deposits.

Tennent GA, Head MW, Bishop M, Hawkins PN, Will RG, Knight R, Peden AH, McCardle LM, Ironside JW, Pepys MB.

J Pathol. 2007 Dec;213(4):376-83.

PMID:
17955450
44.

Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice.

Tennent GA, Hutchinson WL, Kahan MC, Hirschfield GM, Gallimore JR, Lewin J, Sabin CA, Dhillon AP, Pepys MB.

Atherosclerosis. 2008 Jan;196(1):248-55. Epub 2007 Jun 22.

PMID:
17588586
45.

Normal circulating serum amyloid P component concentration in systemic sclerosis.

Tennent GA, Dziadzio M, Triantafillidou E, Davies P, Gallimore JR, Denton CP, Pepys MB.

Arthritis Rheum. 2007 Jun;56(6):2013-7.

46.

Beta-edge interactions in a pentadecameric human antibody V kappa domain.

James LC, Jones PC, McCoy A, Tennent GA, Pepys MB, Famm K, Winter G.

J Mol Biol. 2007 Mar 30;367(3):603-8. Epub 2006 Nov 3.

PMID:
17292396
47.

Is leptin an important physiological regulator of CRP?

Hutchinson WL, Coll AP, Gallimore JR, Tennent GA, Pepys MB.

Nat Med. 2007 Jan;13(1):17-8; author reply 19-21. No abstract available.

PMID:
17206123
48.

Human plasma fibrinogen is synthesized in the liver.

Tennent GA, Brennan SO, Stangou AJ, O'Grady J, Hawkins PN, Pepys MB.

Blood. 2007 Mar 1;109(5):1971-4. Epub 2006 Nov 2.

49.

Organ transplantation in hereditary apolipoprotein AI amyloidosis.

Gillmore JD, Stangou AJ, Lachmann HJ, Goodman HJ, Wechalekar AD, Acheson J, Tennent GA, Bybee A, Gilbertson J, Rowczenio D, O'Grady J, Heaton ND, Pepys MB, Hawkins PN.

Am J Transplant. 2006 Oct;6(10):2342-7. Epub 2006 Aug 21.

50.

C-reactive protein and cardiovascular disease: weighing the evidence.

Lowe GD, Pepys MB.

Curr Atheroscler Rep. 2006 Sep;8(5):421-8. Review.

PMID:
16901413

Supplemental Content

Loading ...
Support Center